{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:11:41Z","timestamp":1773231101661,"version":"3.50.1"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The NadA adhesin is a major component of 4CMenB, a novel vaccine to prevent meningococcus serogroup B (MenB) infection. Under\n            <jats:italic>in vitro<\/jats:italic>\n            growth conditions,\n            <jats:italic>nadA<\/jats:italic>\n            is repressed by the regulator NadR and poorly expressed, resulting in inefficient killing of MenB strains by anti-NadA antibodies. Interestingly, sera from children infected with strains that express low levels of NadA in laboratory growth nevertheless recognize the NadA antigen, suggesting that NadA expression during infection may be different from that observed\n            <jats:italic>in vitro<\/jats:italic>\n            . In a strain panel covering a range of NadA levels, repression was relieved through deleting\n            <jats:italic>nadR<\/jats:italic>\n            . All\n            <jats:italic>nadR<\/jats:italic>\n            knockout strains expressed high levels of NadA and were efficiently killed by sera from subjects immunized with 4CMenB. A selected MenB strain, NGP165, mismatched for other vaccine antigens, is not killed by sera from immunized infants when the strain is grown\n            <jats:italic>in vitro<\/jats:italic>\n            . However, in an\n            <jats:italic>in vivo<\/jats:italic>\n            passive protection model, the same sera effectively protected infant rats from bacteremia with NGP165. Furthermore, we identify a novel hydroxyphenylacetic acid (HPA) derivative, reported by others to be produced during inflammation, which induces expression of NadA\n            <jats:italic>in vitro<\/jats:italic>\n            , leading to efficient antibody-mediated killing. Finally, using bioluminescent reporters,\n            <jats:italic>nadA<\/jats:italic>\n            expression in the infant rat model was induced\n            <jats:italic>in vivo<\/jats:italic>\n            at 3 h postinfection. Our results suggest that during infectious disease, NadR repression is alleviated due to niche-specific signals, resulting in high levels of NadA expression from any\n            <jats:italic>nadA<\/jats:italic>\n            -positive (\n            <jats:italic>nadA<\/jats:italic>\n            <jats:sup>+<\/jats:sup>\n            ) strain and therefore efficient killing by anti-NadA antibodies elicited by the 4CMenB vaccine.\n          <\/jats:p>","DOI":"10.1128\/iai.01085-12","type":"journal-article","created":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T04:43:06Z","timestamp":1355200986000},"page":"560-569","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":55,"title":["Transcriptional Regulation of the\n            <i>nadA<\/i>\n            Gene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine"],"prefix":"10.1128","volume":"81","author":[{"given":"Luca","family":"Fagnocchi","sequence":"first","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Biolchi","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ferlicca","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Boccadifuoco","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunella","family":"Brunelli","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Brier","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Norais","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Chiarot","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Bensi","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Simon","family":"Kroll","sequence":"additional","affiliation":[{"name":"Departments of Paediatrics and Microbiology, Faculty of Medicine, Wright-Fleming Institute, Imperial College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Donnelly","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia Monica","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Delany","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnotics, Research Center, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441807"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(00)00163-6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/511646"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.55.1.174-180.1987"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"e_1_3_3_8_2","unstructured":"EspositoSVesikariTKimuraAYpmaEToneattoDDullP. 2010. Tolerability of a three-dose schedule of an investigational multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial p 168. Abstr. 17th International Pathogenic Neisseria Conference (IPNC) Banff Alberta Canada."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/656741"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181f59f6d"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020407"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021911"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915162107"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013758107"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1327"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1367"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1385"},{"key":"e_1_3_3_19_2","first-page":"17","article-title":"Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci","author":"Donnelly J","year":"2011","unstructured":"DonnellyJMediniDGiulianiMMBoccadifuocoGStellaMFrosiGComanducciMBambiniSMuzziAPizzaMRappuoliRFindlowJBorrowRGilchristSThompsonDLedroitMHongETahaMKAbadRVazquezJMastrantonioPStefanelliPFazioCCarannanteAOksnesJCaugantDAClausHVogelU. 2011. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci, p 17\u201318. Abstr. 11th European Monitoring Group on Meningococci Congress, Ljubljana, Slovenia.","journal-title":"Abstr. 11th European Monitoring Group on Meningococci Congress, Ljubljana, Slovenia"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.092"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000710"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.06.002"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(02)02659-5"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.06161-11"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/424464"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2008.06468.x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1103\/PhysRevLett.97.236804"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.185.20.6032-6041.2003"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi300656w"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21256"},{"key":"e_1_3_3_31_2","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow R","year":"2005","unstructured":"BorrowRAabergeISSantosGFEudeyTLOsterPGlennieAFindlowJHoibyEARosenqvistEBalmerPMartinD. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12:970\u2013976.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.11.5664-5675.1999"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704270200"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.11.6487"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.056"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2004.04423.x"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.3904"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1207810"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0109030"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025089"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1041"}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.01085-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.01085-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T20:14:24Z","timestamp":1646424864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.01085-12"}},"subtitle":[],"editor":[{"given":"A.","family":"Camilli","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1128\/IAI.01085-12"],"URL":"https:\/\/doi.org\/10.1128\/iai.01085-12","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"2012-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}